The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Jin, Zhinan ^a   Smith, Lucas K ^a   Rajwanshi, Vivek K ^a   Kim, Baek ^b   Deval, Jerome ^a  

^a Alios BioPharma Inc   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; FAVIPIRAVIR; GUANOSINE; GUANOSINE TRIPHOSPHATE; RIBONUCLEOTIDE; RNA;

ARTICLE; BASE PAIRING; DRUG ACTIVITY; DRUG MECHANISM; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS A; KINETICS; MOLECULAR INTERACTION; MUTAGENIC ACTIVITY; NONHUMAN; RNA SYNTHESIS;

AMIDES; ANIMALS; ANTIMETABOLITES; ANTIVIRAL AGENTS; BASE PAIR MISMATCH; BASE PAIRING; DNA-DIRECTED DNA POLYMERASE; HUMANS; INFLUENZA A VIRUS; POLYPHOSPHATES; PYRAZINES; RIBAVIRIN; SF9 CELLS; SPODOPTERA; SUBSTRATE SPECIFICITY;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84880006467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068347     Document Type: Article

References (46)

1. He G, Qiao J, Dong C, He C, Zhao L, et al. (2008) Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 77: 72-76.
2. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, et al. (2007) Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297: 1435-1442.
3. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O, (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15: 155-162.
4. Dias A, Bouvier D, Crepin T, McCarthy AA, Hart DJ, et al. (2009) The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458: 914-918.
5. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, et al. (2009) Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458: 909-913.
6. Desselberger U, Racaniello VR, Zazra JJ, Palese P, (1980) The 3′ and 5′-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity. Gene 8: 315-328.
7. Robertson JS, (1979) 5′ and 3′ terminal nucleotide sequences of the RNA genome segments of influenza virus. Nucleic Acids Res 6: 3745-3757.
8. Honda A, Ueda K, Nagata K, Ishihama A, (1987) Identification of the RNA polymerase-binding site on genome RNA of influenza virus. J Biochem 102: 1241-1249.
9. Hsu MT, Parvin JD, Gupta S, Krystal M, Palese P, (1987) Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. Proc Natl Acad Sci U S A 84: 8140-8144.
10. Fodor E, Pritlove DC, Brownlee GG, (1995) Characterization of the RNA-fork model of virion RNA in the initiation of transcription in influenza A virus. J Virol 69: 4012-4019.
11. Noble E, Mathews DH, Chen JL, Turner DH, Takimoto T, et al. (2011) Biophysical analysis of influenza A virus RNA promoter at physiological temperatures. J Biol Chem 286: 22965-22970.
12. Aggarwal S, Bradel-Tretheway B, Takimoto T, Dewhurst S, Kim B, (2010) Biochemical characterization of enzyme fidelity of influenza A virus RNA polymerase complex. PLoS One 5: e10372.
13. Hwang JS, Yamada K, Honda A, Nakade K, Ishihama A, (2000) Expression of functional influenza virus RNA polymerase in the methylotrophic yeast Pichia pastoris. J Virol 74: 4074-4084.
14. Olson AC, Rosenblum E, Kuchta RD, (2010) Regulation of influenza RNA polymerase activity and the switch between replication and transcription by the concentrations of the vRNA 5′ end, the cap source, and the polymerase. Biochemistry 49: 10208-10215.
15. Zhang S, Weng L, Geng L, Wang J, Zhou J, et al. (2010) Biochemical and kinetic analysis of the influenza virus RNA polymerase purified from insect cells. Biochem Biophys Res Commun 391: 570-574.
16. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46: 977-981.
17. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, et al. (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51: 845-851.
18. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, et al. (2009) T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82: 95-102.
19. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, et al. (2013) T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses in Vitro. J Virol.
20. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49: 981-986.
21. Bradel-Tretheway BG, Kelley Z, Chakraborty-Sett S, Takimoto T, Kim B, et al. (2008) The human H5N1 influenza A virus polymerase complex is active in vitro over a broad range of temperatures, in contrast to the WSN complex, and this property can be attributed to the PB2 subunit. J Gen Virol 89: 2923-2932.
22. Brownlee GG, Sharps JL, (2002) The RNA polymerase of influenza a virus is stabilized by interaction with its viral RNA promoter. J Virol 76: 7103-7113.
23. Heck JA, Lam AM, Narayanan N, Frick DN, (2008) Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob Agents Chemother 52: 1901-1911.
24. Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, et al. (2011) Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 108: 15366-15371.
25. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, et al. (2010) Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28: 600-605.
26. De Clercq E, (2012) Human viral diseases: what is next for antiviral drug discovery? Curr Opin Virol 2: 572-579.
27. Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, et al. (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A 108: 20509-20513.
28. Arnold JJ, Cameron CE, (2004) Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry 43: 5126-5137.
29. Jin Z, Deval J, Johnson KA, Swinney DC, (2011) Characterization of the elongation complex of dengue virus RNA polymerase: assembly, kinetics of nucleotide incorporation, and fidelity. J Biol Chem 286: 2067-2077.
30. Crotty S, Cameron CE, Andino R, (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98: 6895-6900.
31. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, et al. (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6: 1375-1379.
32. Maag D, Castro C, Hong Z, Cameron CE, (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276: 46094-46098.
33. Vignuzzi M, Stone JK, Andino R, (2005) Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res 107: 173-181.
34. Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, et al. (2005) Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 67: 38-45.
35. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, et al. (2011) Ribavirin can be mutagenic for arenaviruses. J Virol 85: 7246-7255.
36. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, et al. (2010) In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54: 2517-2524.
37. Graci JD, Cameron CE, (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16: 37-48.
38. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, et al. (2008) Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3: e3725.
39. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
40. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y, (2009) Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53: 202-209.
41. Julander JG, Smee DF, Morrey JD, Furuta Y, (2009) Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 82: 169-171.
42. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, et al. (2011) T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 55: 782-787.
43. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, et al. (2011) Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl Trop Dis 5: e1342.
44. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, et al. (2012) Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424: 777-780.
45. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, et al. (2009) Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 64: 741-746.
46. Parker WB, (2005) Metabolism and antiviral activity of ribavirin. Virus Res 107: 165-171.